Leonardsen, Esten H. http://orcid.org/0000-0002-5099-116X
Persson, Karin
Grødem, Edvard
Dinsdale, Nicola
Schellhorn, Till
Roe, James M.
Vidal-Piñeiro, Didac http://orcid.org/0000-0001-9997-9156
Sørensen, Øystein http://orcid.org/0000-0003-0724-3542
Kaufmann, Tobias http://orcid.org/0000-0002-4003-1018
Westman, Eric http://orcid.org/0000-0002-3115-2977
Marquand, Andre
Selbæk, Geir http://orcid.org/0000-0001-6511-8219
Andreassen, Ole A. http://orcid.org/0000-0002-4461-3568
Wolfers, Thomas
Westlye, Lars T. http://orcid.org/0000-0001-8644-956X
Wang, Yunpeng http://orcid.org/0000-0001-9831-1090
Funding for this research was provided by:
University of Oslo | Livsvitenskap, Universitetet i Oslo (4MENT, 4MENT)
Ministry of Health and Care Services | Helse Sør-Øst RHF (2019101)
Deutsche Forschungsgemeinschaft (Emmy Noether 513851350)
Norges Forskningsråd (300767, 302854)
EC | Horizon 2020 Framework Programme (802998)
Article History
Received: 10 October 2023
Accepted: 23 April 2024
First Online: 2 May 2024
Competing interests
: K.P. report work with Roche BN29553 and Novo Nordisk NN6535-4730 trials; All other authors declare that they have no competing interests.